However, future studies to monitor the mutational profile, neoantigen landscape, microenvironment, and systemic immunologic effects of WEE1 inhibition in preclinical models and in patients with SCLC will be valuable to further inform clinical translational strategies for optimal deployment of WEE1 inhibitors with immunotherapy in this setting. This evidence concerns the gene WEE1 and small cell lung carcinoma.